315. Scaling up clinical research capacity in Africa requires more non-communicable disease studies.
作者: Gabriel Seidman.;Roger Chenn.;Sophia David.;Matthew Lee.;Josh Leffler.;Magdalena Moore.;Sophia Stumpf.;Giridhar Viswanathan.;Muhammad Ali Pate.;Michel Sidibé.;Tariro Makadzange.;Romina Mariano.;Kyle Daniels.;Megan Akodu.;Shan Soe-Lin.
来源: Lancet. 2025年405卷10486期1211-1213页 317. Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial.
作者: Mohamed Abdel-Fattah.;Christopher Chapple.;David Cooper.;Suzanne Breeman.;Helen Bell-Gorrod.;Preksha Kuppanda.;Karen Guerrero.;Simon Dixon.;Nikki Cotterill.;Karen Ward.;Hashim Hashim.;Ash Monga.;Karen Brown.;Marcus Drake.;Andrew Gammie.;Alyaa Mostafa.;Rebecca Bruce.;Victoria Bell.;Christine Kennedy.;Suzanne Evans.;Graeme MacLennan.;John Norrie.; .
来源: Lancet. 2025年405卷10484期1057-1068页
Overactive bladder is a common problem affecting women worldwide, with a negative effect on their social and professional lives. Before considering invasive treatments, guidelines recommend urodynamics to identify detrusor overactivity. However, the clinical-effectiveness and cost-effectiveness of urodynamics has never been robustly assessed in this cohort of women. We aimed to compare the clinical-effectiveness and cost-effectiveness of urodynamics plus comprehensive clinical assessment (CCA) versus CCA only in the management of women with refractory overactive bladder symptoms.
|